Drug development

#Antibodies #Covid-19 #Drug development #Drug discovery #Therapies #Vaccines

Covid-19 response speed sets a new standard in drug discovery

    This paid-for advertorial by Berkeley Lights appeared in DDW Volume 22, Issue 2 – Spring 2021 The Covid-19 pandemic has illuminated how a coordinated response to infectious diseases can result in the development and commercialisation of novel vaccines and therapies at record pace. Several therapeutic antibodies and… Read More

#Covid-19 #Exclusive Content

#Drug development #Drug discovery #Research

New protein degradation centre to lead drug discovery revolution

A new translational research centre aims to bolster the University of Dundee’s drug discovery position. The Centre for Targeted Protein Degradation (CeTPD) will contain the latest facilities to allow Professor Alessio Ciulli and colleagues to expand their pioneering work in an area that has attracted billions of pounds of investment… Read More

#News

#Antibody #Bacteria #Drug development #Drug discovery #Research study

New model can predict how bacteria develop antibiotic resistance

Using theoretical models of bacterial metabolism and reproduction, scientists can predict the type of resistance that bacteria will develop when they are exposed to antibiotics. This has now been shown by an Uppsala University research team, in collaboration with colleagues in Cologne, Germany. The study is published in the journal… Read More

#News

#Cancer research #Drug delivery #Drug development #Drug discovery #Research

Karen Vousden wins first Women in Cancer Research award

Francis Crick Institute group leader Karen Vousden has been awarded the first Pezcoller-Marina Larcher Fogazzaro-EACR Women in Cancer Research Award. This new award celebrates a researcher who has demonstrated academic excellence and achievements in the field of cancer research and who has, through leadership or by example, furthered the advancement… Read More

#Cancer Research #News

#Clinical trial #Depression #Drug development #Drug discovery #Research

Magic mushroom compound performs as well as leading antidepressant

In a small study carried out by researchers at the Centre for Psychedelic Research at Imperial College London, it was found that psilocybin, the active compound in magic mushrooms, may be at least as effective as a leading antidepressant medication in a therapeutic setting. In a rigorous trial which assessed… Read More

#News

#Biopharmaceuticals #Data #Drug development #Life sciences

Price control could cut medicine development by 88% in California

Researchers from Biocom California and the California Life Sciences Association (CLSA) have released data analysing the potential impact of international reference pricing (foreign price controls) on California’s biopharmaceutical innovation ecosystem, including investment into small company capital formation and the new drug development pipeline. The analysis shows that implementing foreign reference… Read More

#News

#AI / data analytics / healthtech / informatics #Diabetes #Drug development #Precision medicine

The power of precision medicine

Listen to this article on the DDW Podcast: Lu Rahman looks at the role precision medicine is playing in how we approach the patient and the way we  treat disease. We hear increasingly about the shift away from one size fits all medicine. It does of course, make perfect… Read More

#Editor's Choice #Exclusive Content #Intelligence #News #Trends & Analysis

#Biopharmaceutical #Biotechnology #Drug development #Drug discovery #Life sciences

Evotec collaborates with Bristol Myers Squibb to advance therapeutics

Evotec has launched beLAB2122, a US$20 million BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency) collaboration with Bristol-Myers Squibb. beLAB2122 brings together academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and… Read More

#News

#Biologics / Biotechnology #Biopharmaceutical #Drug development #Drug discovery #Life sciences

Investment helps establish animal alternative skin testing technology

A near-£1 million investment will help University of Dundee spinout company Ten Bio to commercialise the human skin culture system it developed to provide a viable alternative for many experiments currently performed on animals. The investment will enable the company to progress its mission to transform the testing of new… Read More

#News

#Drug development #Drug discovery #Flow Cytometry #Miltenyi Biotec #Narrated podcasts

Flow Cytometry in Drug Discovery

This narrated article is called “Why flow cytometry in drug discovery is a real life-saver”, in which Roy, Global Product Manager at Miltenyi Biotec, outlines the benefits of flow cytometry, offering case study examples for its use. Capable of boasting high-throughput, accurate, multiparameter and highly reproducible results, it’s time for… Read More

#Podcasts

Cytometry
#Biologics / Biotechnology #Biotechnology #Drug development #Drug discovery #Flow Cytometry #High throughput screening #Podcast

DDW podcast: Flow cytometry in drug discovery

The latest free to listen to DDW podcast episode, titled Flow Cytometry in Drug Discovery, covers an article written by Urmi Roy for DDW, read aloud by Megan Thomas. This article is called “Why flow cytometry in drug discovery is a real life-saver”, in which Roy, Global Product Manager at… Read More

#News

#Cancer #Cancer research #Clinical trial #Drug development #Drug discovery

Virus therapy shows promise against inoperable skin cancers

Early results show that a new combination drug therapy is safe and effective against advanced skin cancer in patients who were unable to have their tumours surgically removed. Researchers say that the drug combination is among the first to demonstrate the potential value of a live common cold virus, a… Read More

#Cancer Research #News

#AI #AI / data analytics / healthtech / informatics #Cancer research #Drug design #Drug development #Drug discovery

First AI-designed immuno-oncology drug enters clinical trials

Exscientia, an artificial intelligence (AI)-driven pharmatech company, has announced the first AI-designed molecule for immuno-oncology to enter human clinical trials, a joint venture co-invented and developed by Exscientia and Evotec. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, includes the application of Exscientia’s… Read More

#Cancer Research #News

#Cancer research #DNA #Drug delivery #Drug development #Drug discovery

Blocking a protein may overcome cancer resistance to PARP inhibitors

Researchers at the Francis Crick Institute have found that blocking a specific protein could increase tumour sensitivity to treatment with PARP inhibitors. Their work published in Science suggests combining treatments could lead to improved therapy for patients with inheritable breast cancers. Some cancers, including certain breast, ovarian and prostate tumours,… Read More

#Cancer Research #Editor's Choice #News

#Clinical trial #Covid-19 #Drug development #Immunology / Virology & Vaccines #Research #Vaccines

NIH begins study of allergic reactions to Covid-19 vaccines

A clinical trial is underway to determine whether people who are highly allergic or have a mast cell disorder are at increased risk for an immediate, systemic allergic reaction to the Moderna or Pfizer-BioNTech Covid-19 vaccines. A systemic allergic reaction to a vaccine occurs in one or more parts of… Read More

#Covid-19 #News

#Clinical trials #Covid-19 #Drug development #Immunology / Virology & Vaccines #Moderna #Vaccines

Moderna’s Covid-19 vaccine antibody persistence data published

Biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, Moderna, has had antibody persistence data out to six months following the second Covid-19 vaccine dose published in The New England Journal of Medicine. “We are pleased that this new data shows antibody persistence through six months following the second dose… Read More

#Covid-19 #News